Matthew Juhascik

Dr. Matthew Juhascik

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 January 2018 in ACS Omega
Verified
Journal Article
Open access
KSKraig E. Strayer
Kraig E. Strayer
HAHeather M. Antonides
Heather M. Antonides
MJMatthew Juhascik
Matthew Juhascik
RDRaminta Daniulaityte
Raminta Daniulaityte
ISIoana Sizemore
Ioana Sizemore
The United States and numerous other countries worldwide are currently experiencing a public health crisis due to the abuse of illicitly manufactured fentanyl (IMF) and its analogues. This manuscript describes the development of a liquid chromatography-tandem mass spectrometry-based method for the multiplex detection of N = 24 IMF analogues and metabolites in whole blood at concentrations as low as 0.1–0.5 ng mL–1. These available IMFs were fentanyl, norfentanyl, furanyl norfentanyl, remifentanil acid, butyryl norfentanyl, remifentanil, acetyl fentanyl, alfentanil, AH-7921, U-47700, acetyl fentanyl 4-methylphenethyl, acrylfentanyl, para-methoxyfentanyl, despropionyl fentanyl (4-ANPP), furanyl fentanyl, despropionyl para-fluorofentanyl, carfentanil, (±)-cis-3-methyl fentanyl, butyryl fentanyl, isobutyryl fentanyl, sufentanil, valeryl fentanyl, para-fluorobutyryl fentanyl, and para-fluoroisobutyryl fentanyl. Most IMF analogues (N = 22) could be easily distinguished from one another; the isomeric forms butyryl/isobutyryl fentanyl and para-fluorobutyryl/para-fluoroisobutyryl fentanyl could not be differentiated. N = 13 of these IMF analogues were quantified for illustrative purposes, and their forensic quality control standards were also validated for limit of detection (0.017–0.056 ng mL–1), limit of quantitation (0.100–0.500 ng mL–1), selectivity/sensitivity, ionization suppression/enhancement (87–118%), process efficiency (60–95%), recovery (64–97%), bias (80%). This flexible, time- and cost-efficient method was successfully implemented at the Montgomery County Coroner’s Office/Miami Valley Regional Crime Laboratory in Dayton, Ohio, where it aided in the analysis of N = 725 postmortem blood samples collected from February 2015 to November 2016.

1 September 2019 in International Journal of Drug Policy
Verified
Journal Article
Closed access
RDRaminta Daniulaityte
Raminta Daniulaityte
RCRobert R. Carlson
Robert R. Carlson
MJMatthew Juhascik
Matthew Juhascik
KSKraig E. Strayer
Kraig E. Strayer
ISIoana Sizemore
Ioana Sizemore

23 July 2021 in Journal of Analytical Toxicology
Verified
Journal Article
Closed access
PDF file
EKElizabeth Kiely
Elizabeth Kiely
MJMatthew Juhascik
Matthew Juhascik
The detection of fentanyl (FEN) and FEN analogs has been widely communicated throughout the scientific community. While most of the reporting has been in relation to overdose deaths, these drugs are commonly detected in impaired driving cases. A retrospective study of impaired driving cases analyzed between 2017 and 2019 produced 270 cases positive for FEN, carfentanil (CFEN) and/or acetylfentanyl (AFEN). FEN was the predominant drug found in these 270 cases (65.5%) with concentrations ranging from less than 1.0 to 64 ng/mL. CFEN was found alone in 6.6% cases with three concentrations above 1.0 ng/mL. AFEN was always found when FEN was positive with concentrations ranging from <1.0 to 9.2 ng/mL. Detailed case histories are provided with corresponding toxicology results. Toxicology results show impaired drivers using multiple drugs with a wide range of observed behaviors. The inclusion of these drugs in routine impaired driver toxicology testing is extremely important when attempting to determine their overall prevalence.

23 July 2022 in Emerging Trends in Drugs, Addictions, and Health
Verified
Journal Article
Open access
LRLance Ruhter
Lance Ruhter
MJMatthew Juhascik
Matthew Juhascik
JWJennifer Watson
Jennifer Watson
KSKaylin Sweeney
Kaylin Sweeney
RDRaminta Daniulaityte
Raminta Daniulaityte
Non-pharmaceutical fentanyl and related drugs (NPF) have contributed to increases in drug-related overdose mortality in the U.S. More data are needed to track the shifting composition of fentanyl-containing drug mixtures. The key aims of the study are to characterize the crime lab data from Montgomery County, Ohio on the increased cases of seized drugs containing mixtures of NPF and tramadol. Crime lab data on seized drugs in Montgomery County, Ohio (2015 - 2020) were analyzed to extract information on cases that tested positive for NPF and tramadol. Descriptive statistics are provided to characterize NPF/tramadol mixtures in terms of the quantity, weight, form of the drug seized (powder, tablet, capsule, residue), and the types of fentanyl analogs and other drugs identified. In December 2017, the first case of NPF/tramadol mixture was identified in the amount of 0.2 g. Sub-sequently, cases containing NPF/tramadol increased significantly to 149 cases in 2018, 102 in 2019, and 134 in 2020. The total yearly amounts of seized NPF/tramadol mixtures increased to 373.27 g in 2018, 2,601.82 g in 2019, and 13,487.62 g in 2020. The majority (72.6%) of the cases were in powder form. There were 15 other drugs identified along with fentanyl with tramadol mixtures, including heroin (38.8%), 5.7% cocaine (5.7%), and methamphetamine (4.9%). The addition of tramadol to NPF may be viewed as a harm mitigation strategy but contributes to the overall unpredictability of the illicit drug supply. According to Ohio legal statutes, identification of schedule IV drugs such as tramadol with fentanyl (schedule II) may provide a reduction in drug-related charges from a felony to a misdemeanor. More research is needed to characterize potential sources of tramadol in NPF-containing drugs.

29 September 2026 in Pathogens
Verified
Journal Article
Open access
PDF file
WHWei-Wen Hsu
Wei-Wen Hsu
.M. Meeds
. Meeds
JKJanani Madhuravasal Krishnan
Janani Madhuravasal Krishnan
SASolomon K Amuzu
Solomon K Amuzu
KFKevin Fedders
Kevin Fedders
JBJason T Blackard
Jason T Blackard
Background: The United States continues to experience a major drug epidemic driven by synthetic opioids, particularly fentanyl. Emerging evidence suggests that opioids alter immune responses and viral pathogenesis. This study evaluated inflammatory and apoptotic markers among individuals living with HIV and/or hepatitis C virus (HCV) infection in the context of opioid/fentanyl exposure. Methods: Whole blood was collected from adults with HIV, HCV, and/or opioid use disorder (OUD), along with healthy controls. Plasma toxicology screening for illicit substances was performed using LC-MS/MS. Inflammatory cytokines and chemokines (IL-6, IL-8, SDF-1α, MIP-1α, MIP-1β, RANTES, and TNF-α) were measured by Luminex, and M30 was measured by ELISA. Biomarkers were compared using the Kruskal–Wallis test, with multivariable regression used to identify independent associations. Results: Among 98 participants, 37.8% had OUD, 53.9% had a history of injection drug use, and 95.9% of toxicology-confirmed opioid users tested positive for fentanyl. Participants with HIV had higher RANTES and lower M30 levels, whereas participants with HCV had higher IL-8, MIP-1β, TNF-α, and M30 levels and lower RANTES. Multivariable analysis identified independent associations of IL-8 with HIV and HCV status, SDF-1α with injection drug use and recent fentanyl exposure, and MIP-1β with HCV status. The number of substances detected was not independently associated with inflammatory marker levels. Conclusions: HIV and HCV were associated with distinct inflammatory and apoptotic profiles in the setting of widespread fentanyl exposure, suggesting that chronic viral infection and opioid exposure contribute to immune dysregulation and may influence disease progression.

3 November 2025 in International Journal of Drug Policy
Verified
Journal Article
Closed access
RDRaminta Daniulaityte
Raminta Daniulaityte
KSKaylin Sweeney
Kaylin Sweeney
PTPatricia Timmons
Patricia Timmons
MHMadeline Hooten
Madeline Hooten
EWElisabeth Williams
Elisabeth Williams
MJMatthew Juhascik
Matthew Juhascik